John Overdeck’s Cellyan Biotechnology HKPD Stock Holding History

John Overdeck’s Portfolio HKPD Stock Details HKPD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,832	Closed	-$6.16K	–	5530
2026 Q1	$6.16K	Sell	10,832 -5,919	-35%	-$4.31K	﹤0.01%	4540
2025 Q4	$13.8K	Buy	+16,751	New	+$18K	﹤0.01%	4018

Other funds holding HKPD

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

John Overdeck's HKPD Position: Q2 2026 in Review

John Overdeck sold out of Cellyan Biotechnology (HKPD) in Q2 2026, closing a stake of 10,832 shares — an estimated $6.16K sold.

John Overdeck first reported a position in HKPD in Q4 2025 and held it in 2 quarters. The position peaked at $13.8K in Q4 2025. 6 funds tracked by Wall St. Rank hold HKPD as of Q2 2026.

John Overdeck reported no remaining Cellyan Biotechnology position as of Q2 2026 after selling out during the quarter.
John Overdeck sold 10,832 Cellyan Biotechnology shares in Q2 2026, an estimated $6.16K.
John Overdeck first reported a position in Cellyan Biotechnology in Q4 2025 and held it in 2 quarters.
John Overdeck's Cellyan Biotechnology position peaked at $13.8K in Q4 2025.
6 funds tracked by Wall St. Rank held Cellyan Biotechnology as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.